Hormone-Loaded MHA Hydrogel Composition for Controlled Release

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing hormone therapies face challenges such as inconsistent dosage delivery, adverse effects, and poor patient compliance due to unsuitable delivery methods like pills, patches, and creams, while subcutaneous hydrogel formulations suffer from absorption and bioavailability issues, affecting stability and shelf life.

Innovation Solution

A crosslinked methacrylate hyaluronic acid (MHA) polymer hydrogel encapsulates hormones like testosterone, providing a controlled release mechanism that bypasses the liver and ensures stable, consistent delivery over an extended period.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If subcutaneous hydrogel formulations are used for hormone delivery, then controlled release and extended duration are achieved, but absorption and bioavailability issues reduce stability and shelf life

Engineering Contradiction:

Improveduration of hormone deliveryVSAvoidstability and shelf life

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent uses a composite hydrogel system combining methacrylated hyaluronic acid (MeHA) polymer matrix with photoinitiator (LAP) and hormone. This composite structure provides both controlled release capability and improved stability, resolving the contradiction between extended duration and reliability.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent modifies the physical and chemical parameters of the hydrogel system by using methacrylated hyaluronic acid with specific molecular weight and degree of methacrylation, along with optimizing photoinitiator concentration and UV exposure parameters. These parameter changes enhance both stability and controlled release performance.

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If traditional hormone delivery methods (pills, patches, creams) are used, then ease of administration is maintained, but inconsistent dosage delivery and frequent applications are required

Engineering Contradiction:

Improveease of administrationVSAvoidduration of hormone delivery

Core Design Contradiction:

Ease of operationVSDuration of action of stationary object

Solution Approach 1:

The patent segments the hormone delivery system into injectable hydrogel microparticles that can be administered once and release hormone over extended periods. This segmentation approach transforms the delivery method while maintaining ease of administration and extending duration significantly.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The hydrogel matrix acts as an intermediary carrier between the hormone and the body, enabling controlled release over time. This intermediary system resolves the contradiction by providing both ease of single-administration and extended duration of action.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Speed

If solubilized hormone injections are used, then immediate hormone delivery is achieved, but frequent doctor visits are required due to rapid tapering below efficacious levels

Engineering Contradiction:

Improvespeed of hormone deliveryVSAvoidfrequency of doctor visits

Core Design Contradiction:

SpeedVSLoss of time

Solution Approach 1:

The patent incorporates the hormone into the hydrogel matrix in advance, creating a reservoir that releases hormone at controlled rates. This preliminary action eliminates the need for frequent re-injections, resolving the contradiction between immediate delivery and reduction of doctor visit frequency.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The hydrogel matrix provides continuous hormone release over extended periods, maintaining therapeutic levels without the rapid tapering seen in solubilized injections. This continuity reduces the frequency of medical interventions while ensuring consistent hormone delivery.

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The MHA hydrogel formulation offers improved absorption, bioavailability, and stability, reducing the need for frequent doctor visits and enhancing patient compliance by maintaining therapeutic hormone levels for months with minimal side effects.

Implementation Method 1

The crosslinked MHA polymer is formed from MHA and sodium hyaluronate and is generated by applying ultraviolet light to an uncrosslinked MHA mixture

Methodology Applied

Scientific EffectPhotopolymerization: Photopolymerisation

Implementation Method 2

subcutaneously inserted hydrogel microparticles are a particularly efficacious mechanism of controlled drug release

Methodology Applied

Scientific EffectDiffusion: Diffusion

Data Source

PatentUS20250319021A1Composition of hydrogel loaded with hormone

Publication Date: 2025.10.16 VITALTE LIFESCIENCES INC

AI summary

Hydrogel compositions that include a crosslinked methacrylate hyaluronic acid (MHA) polymer and a hormone are described. The crosslinked MHA polymer is formed from MHA and sodium hyaluronate. The hormone is encapsulated by the crosslinked MHA polymer. The crosslinked MHA polymer is generated by applying ultraviolet light to an uncrosslinked MHA mixture. The uncrosslinked MHA mixture includes the hormone, MHA and sodium hyaluronate.